The significance of low‐level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD)
Open Access
- 26 January 2014
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 15 (7) , 406-416
Abstract
Objectives: The aim of the study was to assess the significance of low‐level viraemia (LLV) and the timing of treatment change in low/middle‐income country (L/MIC) compared with high‐income country (HIC) settings.Methods: Patients with virological control following commencement of combination antiretroviral therapy (cART) were included in the study. LLV was defined as undetectable viral load ( 1000 copies/mL. Kaplan−Meier plots of time to virological failure by prior LLV and income category were generated. Regimen changes in the setting of LLV were compared between sites. Sensitivity analysis of rates of LLV and virological failure by person‐years and number of tests was conducted for differing definitions of LLV and virological failure.Results: A total of 1748 patients from HICs and 823 patients from L/MICs were included in the study. One hundred and ninety‐six (11.2%) HIC participants and 36 (4.4%) L/MIC participants experienced at least one episode of LLV. Of the patients who underwent regimen switch in HIC settings, the majority changed from a nucleoside reverse transcriptase inhibitor (NRTI)/protease inhibitor (PI) regimen to an NRTI/nonnucleoside reverse transcriptase inhibitor (NNRTI) regimen (26.8%). Very few switches were made in L/MIC settings. Rates of LLV were significantly higher for HICs compared with L/MICs per 1000 person‐years (28.6 and 9.9 per 1000 person‐years, respectively), but not in terms of the number of tests (9.4 and 7.2 per 1000 tests, respectively). Rates of virological failure per test were significantly higher for L/MICs compared with HICs (30.7 vs. 19.6 per 1000 tests, respectively; P < 0.001). LLV was a significant predictor of virological failure at 2 years in L/MICs [0.25; 95% confidence interval (CI) 0.11–0.50; P = 0.043] but not in HICs (0.13; 95% CI 0.08‐0.22; P = 0.523).Conclusions: LLV is weakly predictive of virological failure at 2 years in L/MICs but not in HICs. This suggests that interventions targeted at subjects with LLV in L/MICs would help to improve treatment outcomes.Keywords
This publication has 20 references indexed in Scilit:
- Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level ViremiaAntimicrobial Agents and Chemotherapy, 2012
- Ultrasensitive Assessment of Residual Low-Level HIV Viremia in HAART-Treated Patients and Risk of Virological FailureJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Episodes of HIV Viremia and the Risk of Non-AIDS Diseases in Patients on Suppressive Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Impact of Low-Level-Viremia on HIV-1 Drug-Resistance Evolution among Antiretroviral Treated-PatientsPLOS ONE, 2012
- Short-Term Clinical Outcomes Among Treatment-Experienced HIV-Positive Patients with Early Low Level ViremiaAIDS Patient Care and STDs, 2012
- Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events AnalysisThe Journal of Infectious Diseases, 2012
- Antiretroviral Drug Resistance in HIV-1–Infected Patients Experiencing Persistent Low-Level Viremia During First-Line TherapyThe Journal of Infectious Diseases, 2011
- Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremiaAIDS, 2011
- Intermittent Episodes of Detectable HIV Viremia in Patients Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based or Protease Inhibitor-Based Highly Active Antiretroviral Therapy Regimens Are Equivalent in Incidence and PrognosisClinical Infectious Diseases, 2005
- Rates of combination antiretroviral treatment change in Australia, 1997–2000HIV Medicine, 2002